Quarterly ResultMay 14, 2026, 04:38 PM
Sutro Biopharma Raises $110M; Q1 Net Loss Halved to $38.5M
AI Summary
Sutro Biopharma, Inc. reported a significant reduction in its net loss for the first quarter of 2026, decreasing to $38.5 million from $76.0 million in the prior year, primarily due to lower operating expenses following its 2025 restructuring plans. The company also successfully completed a public offering in February 2026, raising approximately $110.0 million in gross proceeds by selling 7.87 million shares of common stock. This capital raise substantially improved its cash position, with unrestricted cash, cash equivalents, and marketable securities increasing to $202.6 million, providing liquidity for at least 12 months, despite an accumulated deficit of over $1 billion.
Key Highlights
- Raised $110.0 million gross proceeds from a public offering of 7,868,383 common shares in February 2026.
- Net loss decreased to $38.5 million in Q1 2026 from $76.0 million in Q1 2025.
- Net loss per share improved to $(2.94) in Q1 2026 from $(9.08) in Q1 2025.
- Total operating expenses fell to $44.2 million in Q1 2026 from $85.9 million in Q1 2025.
- Research and development expenses decreased to $36.6 million in Q1 2026 from $51.6 million in Q1 2025.
- Unrestricted cash, cash equivalents, and marketable securities totaled $202.6 million as of March 31, 2026.
- Net cash used in operating activities reduced to $42.3 million in Q1 2026 from $67.9 million in Q1 2025.
- Accumulated deficit increased to $1,016.4 million as of March 31, 2026.
Price Impact
More from STRO